Shares of drug developer Xoma ( XOMA) jumped more than 7% after the company said it's expanding its collaboration with Schering-Plough ( SGP) in the development of antibodies to treat cancer and immune diseases.

The stock gained 17 cents to $2.52 Wednesday morning.

Xoma has received upfront payments for each additional collaboration program and will also receive research funding for each project as well as success-based milestones and royalties on sales of products that result from the collaboration, the company said in a press release Wednesday morning.

"We have made significant progress on the first product program since its initiation with Schering-Plough in mid-2006,'' said Xoma. "We look forward to advancing the new programs in a similar high quality and expedited manner.''

Xoma and Schering-Plough announced their initial collaboration last May. Under the agreement, Xoma will discover and develop therapeutic antibodies to treat multiple disease targets selected by Schering-Plough, conduct early studies to support regulatory filings, and produce the antibodies for initial clinical trials.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective